FOLLOW US
Behavioral health markets, trials, policy, and signals.
Coverage Pharma / Psychedelics / Cannabis
Digital Health / Regulation / Research
What moved. Why it matters. What to watch next.
https://t.co/I1MJDVHPFL
Compass expects psilocybin revenue in late Q2 or Q3 2027, after FDA, DEA, state and billing steps. It says it does not know whether FDA will set a review date, and that much site work waits on final scheduling. Written guidance remains first half of 2027, subject to FDA approval.
Two cost models of psilocybin for treatment-resistant depression use the same single 25 mg dose. One has it adding about $3,640 per patient over 12 months, the other saving about $7,000 over 6. Both call it cost-effective.
ARPA-H's first two ibogaine awards went to a Cancún clinic and Mark Cuban's Cost Plus Drug Company.
Beond: up to $800,000 for records from 250 treated patients. Cost Plus: up to $4.2 million toward a U.S.-made ibogaine product for PTSD.
GH Research's GH001 pivotal start has moved into 2027, pending an FDA meeting in Q1. The planned trials use one fixed dose on a new device with a Week 4 endpoint, not the three-step vaporizer regimen behind the 15.5-point Phase 2b result.
Neurosterix told Behavioral Wire that RTW Investments led the round. Janus Henderson Investors, Google Ventures (GV), Ikarian Capital, Affinity Asset Advisors and Dellora Investments joined as new investors
Yesterday, Neurosterix closed a $105 million Series B, mainly to take NTX-253 into Phase 2. The company has published no Phase 1 data, named no investors and not disclosed a Phase 2 design.
On November 11, NRx said it had started commercial sales activity with a 17-person sales force, with shipments scheduled to begin in January 2027. It disclosed no price, booked orders, named customers, revenue or volumes.
The DEA has proposed a 2027 ibogaine quota of 12,002 grams, up from 210 grams in 2026.
W. Bryan Hubbard of Americans for Ibogaine reads the increase as a political outcome. The DEA notice cites research and clinical-trial activity.
@BrainsWay's balance-sheet investments in clinic management companies and a home-neuromodulation developer reached $28.9 million on Sept. 30, up from $14.7 million at the end of 2025.
The DEA has proposed a 2027 national production ceiling for ibogaine of 12,002 grams, against the 210 grams established for 2026, about 57 times higher. MDMA would nearly triple, psilocybin and psilocyn would rise 20 and 17 percent, and DMT, 5-MeO-DMT and LSD would not move.
@JNJNews reports that Study 452, the second pivotal Phase 3 trial of Caplyta (lumateperone) in bipolar I mania, met its primary and key secondary endpoints.
A Johns Hopkins team coded 600 public comments from the five most-commented FDA reviews of 2020 to 2024: 90.2% supported approval. The study's own appendix of 44 advisory committee reviews shows comment volume tracking committee votes in no consistent way. In the five cases,
Big ups to Behavioral Wire (@behavioralwire) for breaking the Compass Pathways NDA filing news first this morning.
New kids on the block already breaking big news.
Give them a follow!